Skip to content

Artivion AORT Other, net

Other, net at other companies

Edwards Lifesciences logo
Edwards LifesciencesEW
$1.7M+143%
ITG
Integer HoldingsITGR
-$106K-251%
Boston Scientific logo
Boston ScientificBSX
$3M+130%
BioLife Solutions logo
BioLife SolutionsBLFS
$3K-70.0%
LivaNova logo
LivaNovaLIVN
$1.69M+3,780%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$116.3M+17.5%
Gross profit$75.4M+18.7%
Operating income$5.8M+170%
Net income$1.4M+381%
EPS (diluted)$0.03+400%

Balance sheet

See full
Cash & equivalents$55.8M+47.9%
Total debt$258.2M-28.8%
Total equity$450.5M+53.1%
Total assets$883.2M+11.6%

Cash flow

See full
Operating cash flow$1.2M+107%
CapEx$8.0M+120%
Free cash flow-$6.8M+66.7%

Valuation

See full
Market cap$1.07B-22.7%
Enterprise value$1.27B-25.5%
P/E91.5×
P/S2.3×-1.2×

Profitability

See full
Gross margin64.6%+0.6pp
Operating margin8.2%+4.1pp
Net margin2.5%+1.5pp
FCF margin-0.1%-2.5pp

Returns & leverage

See full
Return on equity3.1%+1.8pp
Debt / equity0.6×-0.7×
Current ratio3.9×-1.7×

Where this comes from

Reported directly by Artivion in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Artivion’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artivion's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artivion's other, net?
Artivion (AORT) reported other, net of -$210K in Q1 2026.
How has Artivion's other, net changed year-over-year?
Artivion's other, net decreased by 18.0% year-over-year, from -$178K to -$210K.
What is the long-term trend for Artivion's other, net?
Over 2 years (2022 to 2025), Artivion's other, net has grown at a 23.4% compound annual growth rate (CAGR), from -$459K to -$699K.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.